APA
Röllig C., Serve H., Hüttmann A., Noppeney R., Müller-Tidow C., Krug U., Baldus C. D., Brandts C. H., Kunzmann V., Einsele H., Krämer A., Schäfer-Eckart K., Neubauer A., Burchert A., Giagounidis A., Krause S. W., Mackensen A., Aulitzky W., Herbst R., Hänel M., Kiani A., Frickhofen N., Kullmer J., Kaiser U., Link H., Geer T., Reichle A., Junghanß C., Repp R., Heits F., Dürk H., Hase J., Klut I., Illmer T., Bornhäuser M., Schaich M., Parmentier S., Görner M., Thiede C., von Bonin M., Schetelig J., Kramer M., Berdel W. E. & Ehninger G. (20160418). Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. : The Lancet. Oncology.
Chicago
Röllig Christoph, Serve Hubert, Hüttmann Andreas, Noppeney Richard, Müller-Tidow Carsten, Krug Utz, Baldus Claudia D, Brandts Christian H, Kunzmann Volker, Einsele Hermann, Krämer Alwin, Schäfer-Eckart Kerstin, Neubauer Andreas, Burchert Andreas, Giagounidis Aristoteles, Krause Stefan W, Mackensen Andreas, Aulitzky Walter, Herbst Regina, Hänel Mathias, Kiani Alexander, Frickhofen Norbert, Kullmer Johannes, Kaiser Ulrich, Link Hartmut, Geer Thomas, Reichle Albert, Junghanß Christian, Repp Roland, Heits Frank, Dürk Heinz, Hase Jana, Klut Ina-Maria, Illmer Thomas, Bornhäuser Martin, Schaich Markus, Parmentier Stefani, Görner Martin, Thiede Christian, von Bonin Malte, Schetelig Johannes, Kramer Michael, Berdel Wolfgang E and Ehninger Gerhard. 20160418. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. : The Lancet. Oncology.
Harvard
Röllig C., Serve H., Hüttmann A., Noppeney R., Müller-Tidow C., Krug U., Baldus C. D., Brandts C. H., Kunzmann V., Einsele H., Krämer A., Schäfer-Eckart K., Neubauer A., Burchert A., Giagounidis A., Krause S. W., Mackensen A., Aulitzky W., Herbst R., Hänel M., Kiani A., Frickhofen N., Kullmer J., Kaiser U., Link H., Geer T., Reichle A., Junghanß C., Repp R., Heits F., Dürk H., Hase J., Klut I., Illmer T., Bornhäuser M., Schaich M., Parmentier S., Görner M., Thiede C., von Bonin M., Schetelig J., Kramer M., Berdel W. E. and Ehninger G. (20160418). Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. : The Lancet. Oncology.
MLA
Röllig Christoph, Serve Hubert, Hüttmann Andreas, Noppeney Richard, Müller-Tidow Carsten, Krug Utz, Baldus Claudia D, Brandts Christian H, Kunzmann Volker, Einsele Hermann, Krämer Alwin, Schäfer-Eckart Kerstin, Neubauer Andreas, Burchert Andreas, Giagounidis Aristoteles, Krause Stefan W, Mackensen Andreas, Aulitzky Walter, Herbst Regina, Hänel Mathias, Kiani Alexander, Frickhofen Norbert, Kullmer Johannes, Kaiser Ulrich, Link Hartmut, Geer Thomas, Reichle Albert, Junghanß Christian, Repp Roland, Heits Frank, Dürk Heinz, Hase Jana, Klut Ina-Maria, Illmer Thomas, Bornhäuser Martin, Schaich Markus, Parmentier Stefani, Görner Martin, Thiede Christian, von Bonin Malte, Schetelig Johannes, Kramer Michael, Berdel Wolfgang E and Ehninger Gerhard. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. : The Lancet. Oncology. 20160418.